Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients
Publication date: Available online 8 January 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Moolchand Kurmi, Archana Sahu, Mayurbhai Kathadbhai Ladumor, Arvind Kumar Bansal, Saranjit SinghAbstractIncompatibility studies of antiretroviral drugs, viz., lamivudine (3TC), emtricitabine (FTC), abacavir sulfate (ABC), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV), efavirenz (EFV) and nevirapine (NVP) were carried out in the presence of ten selected excipients, i.e., microcrystalline cellulose, lactose monohydrate, starch, magnesium stearate, sodium lauryl sulfate, sodium starch glycolate, croscar...
Source: Journal of Pharmaceutical and Biomedical Analysis - January 9, 2019 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
Conclusion Switching from TDF/FTC to ABC/3TC resulted in significantly increased LDL, HDL, and TC levels. PMID: 27904105 [PubMed - in process] (Source: Internal Medicine)
Source: Internal Medicine - December 3, 2016 Category: Internal Medicine Tags: Intern Med Source Type: research

Abacavir/Lamivudine
EPZICOM Tablets contain the following 2 synthetic nucleoside analogues: abacavir sulfate (ZIAGEN, also a component of TRIZIVIR) and lamivudine (also known as EPIVIR or 3TC) with inhibitory activity against HIV-1. EPZICOM Tablets are for oral administration. Each orange, film-coated tablet contains the active ingredients 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine, and the inactive ingredients magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film (OPADRY® orange YS-1-13065-A) that is made of FD&C Yellow No. 6, hypromellose, polyethylene gl...
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research

Abacavir/Lamivudine/ Zidovudine
Abacavir/lamivudine/zidovudine (Trizivir) is a fixed-dose tablet that contains three synthetic nucleoside analogues: abacavir sulfate, lamivudine, and zidovudine. Each tablet contains abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg, each of which inhibits HIV-1 viral reverse transcriptase. [#] (Source: Aids Info Drugs)
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post‐marketing surveillance in Japan
ConclusionsThe post‐marketing surveillance indicated that the incidence of both ischaemic heart disease and hypersensitivity associated with Epzicom was considerably low, suggesting that this drug can be safely used in the Japanese population. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - March 3, 2014 Category: Drugs & Pharmacology Authors: Tomoko Kurita, Tomomi Kitaichi, Takako Nagao, Toshiyuki Miura, Yoshifumi Kitazono Tags: Original Report Source Type: research

In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity.
Abstract Several studies have reported an increased incidence of auditory dysfunction among HIV/AIDS patients. We used auditory HEI-OC1 cells in cell viability, flow cytometry and caspases 3/7-activation studies to investigate the potential ototoxicity of fourteen HIV antiretroviral agents: Abacavir, AZT, Delavirdine, Didenosine, Efavirenz, Emtricitabine, Indinavir, Lamivudine, Nefinavir, Nevirapine, Tenofovir, Ritonavir, Stavudine and Zalcitabine, as well as combinations of these agents as used in the common anti-HIV cocktails Atripla™, Combivir™, Epzicom™, Trizivir™, and Truvada™. Our results s...
Source: Hearing Research - January 31, 2014 Category: Audiology Authors: Thein P, Kalinec GM, Park C, Kalinec F Tags: Hear Res Source Type: research